

## Nylestriol

## Chemical Properties


CAS No. : 39791-20-3

Formula: C<sub>25</sub>H<sub>32</sub>O<sub>3</sub>

Molecular Weight: 380.52

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Nylestriol (LY 49825) is an agonist of estrogen receptor.
Targets(IC50)	Estrogen Receptor/ERR
In vivo	Nylestriol promoted formation of new bone, increase bone density, and improve bone microstructure damage in OVX rats when combining with Simvastatin[1].

## Solubility Information

Solubility	DMSO: 252.5 mg/mL (663.57 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2 mg/mL (5.26 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

---

	<b>1mg</b>	<b>5mg</b>	<b>10mg</b>
1 mM	2.628 mL	13.1399 mL	26.2798 mL
5 mM	0.5256 mL	2.628 mL	5.256 mL
10 mM	0.2628 mL	1.314 mL	2.628 mL
50 mM	0.0526 mL	0.2628 mL	0.5256 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Li XF, et al. Effects of Simvastatin and Combination of Simvastatin and Nylestriol on Bone Metabolism in Ovariectomized Rats. *Am J Ther.* 2016 Nov/Dec;23(6):e1630-e1636.

Liao EY, et al. The effect of low dose nylestriol-levonorgestrel replacement therapy on bone mineral density in women with postmenopausal osteoporosis. *Endocr Res.* 2003 May;29(2):217-26.

Yang K, Liao E, Zhou H. [Effect of nylestriol and levonorgestrel on the expression of estrogen receptor subtypes in human osteosarcoma MG-63 cell lines]. *Zhong Nan Da Xue Xue Bao Yi Xue Ban.* 2010 Dec;35(12):1248-53.

Cheng GJ, et al. Nylestriol replacement therapy in postmenopausal women. A three-year prospective study. *Chin Med J (Engl).* 1993 Dec;106(12):911-6.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481